{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:28:57Z","timestamp":1790227737972,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Leon Fredericq fund"},{"name":"Anti-Cancer Center ULg"},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek \u2013 Vlaanderen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Belgian Foundation Against Cancer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13045-016-0281-2","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T12:07:32Z","timestamp":1467634052000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease"],"prefix":"10.1186","volume":"9","author":[{"given":"Gilles","family":"Fransolet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9gory","family":"Ehx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Somja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lo\u00efc","family":"Delens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Hannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9phine","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Drion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Caers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Humblet-Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Delvenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Conteduca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"key":"281_CR1","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1038\/leu.2012.135","volume":"26","author":"F Baron","year":"2012","unstructured":"Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462\u20138.","journal-title":"Leukemia"},{"key":"281_CR2","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED, Seattle Marrow Transplant T: Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529\u201333.","journal-title":"N Engl J Med"},{"key":"281_CR3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2005.08.136","volume":"23","author":"F Baron","year":"2005","unstructured":"Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R, Woolfrey AE, Chauncey TR, Flowers MED, Mielcarek M, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993\u20132003.","journal-title":"J Clin Oncol"},{"key":"281_CR4","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2010.187","volume":"24","author":"S Thepot","year":"2010","unstructured":"Thepot S, Zhou J, Perrot A, Robin M, Xhaard A, de Latour RP, Ades L, Ribaud P, Petropoulou AD, Porcher R, Socie G. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010;24:1852\u20138.","journal-title":"Leukemia"},{"key":"281_CR5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-014-0059-3","volume":"7","author":"YR Lai","year":"2014","unstructured":"Lai YR, Chen YH, Hu DM, Jiang M, Liu QF, Liu L, Hou J, Schwarzenberger P, Li QC, Zhang ZM, et al. Multicenter phase II study of a combination of cyclosporine a, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG). J Hematol Oncol. 2014;7:59.","journal-title":"J Hematol Oncol"},{"key":"281_CR6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-014-0098-9","volume":"8","author":"F Baron","year":"2015","unstructured":"Baron F, Zachee P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, et al. Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2\u00a0Gy TBI or ATG plus 8\u00a0Gy TLI: a phase II randomized study from the Belgian Hematological Society. J Hematol Oncol. 2015;8:4.","journal-title":"J Hematol Oncol"},{"key":"281_CR7","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","volume":"29","author":"JR Wingard","year":"2011","unstructured":"Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socie G. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29:2230\u20139.","journal-title":"J Clin Oncol"},{"key":"281_CR8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.bbmt.2008.07.015","volume":"14","author":"JA Perez-Simon","year":"2008","unstructured":"Perez-Simon JA, Encinas C, Silva F, Arcos MJ, Diez-Campelo M, Sanchez-Guijo FM, Colado E, Martin J, Vazquez L, del Canizo C, et al. Prognostic factors of chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation: the national institutes health scale plus the type of onset can predict survival rates and the duration of immunosuppressive therapy. Biol Blood Marrow Transplant. 2008;14:1163\u201371.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13045-015-0207-4","volume":"8","author":"F Baron","year":"2015","unstructured":"Baron F, Labopin M, Ruggeri A, Mohty M, Sanz G, Milpied N, Bacigalupo A, Rambaldi A, Bonifazi F, Bosi A, et al. Unrelated cord blood transplantation for adult patients with acute myeloid leukemia: higher incidence of acute graft-versus-host disease and lower survival in male patients transplanted with female unrelated cord blood-a report from Eurocord, the Acute Leukemia Working Party, and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. J Hematol Oncol. 2015;8:107.","journal-title":"J Hematol Oncol"},{"key":"281_CR10","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1182\/blood-2014-01-514752","volume":"124","author":"G Socie","year":"2014","unstructured":"Socie G, Ritz J. Current issues in chronic graft-versus-host disease. Blood. 2014;124:374\u201384.","journal-title":"Blood"},{"key":"281_CR11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12:443\u201358.","journal-title":"Nat Rev Immunol"},{"key":"281_CR12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2014-09-599159","volume":"125","author":"A Masson de","year":"2015","unstructured":"de Masson A, Bouaziz JD, Le Buanec H, Robin M, O\u2019Meara A, Parquet N, Rybojad M, Hau E, Monfort JB, Branchtein M, et al. CD24(hi)CD27(+) and plasmablast-like regulatory B cells in human chronic graft-versus-host disease. Blood. 2015;125:1830\u20139.","journal-title":"Blood"},{"key":"281_CR13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","volume":"120","author":"K Matsuoka","year":"2010","unstructured":"Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, Cutler C, Ho VT, Alyea EP, Antin JH, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010;120:1479\u201393.","journal-title":"J Clin Invest"},{"key":"281_CR14","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2012.41.7071","volume":"30","author":"MC Pasquini","year":"2012","unstructured":"Pasquini MC, Devine S, Mendizabal A, Baden LR, Wingard JR, Lazarus HM, Appelbaum FR, Keever-Taylor CA, Horowitz MM, Carter S, et al. Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012;30:3194\u2013201.","journal-title":"J Clin Oncol"},{"key":"281_CR15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/sj.bmt.1703154","volume":"28","author":"A Urbano-Ispizua","year":"2001","unstructured":"Urbano-Ispizua A, Brunet S, Solano C, Moraleda JM, Rovira M, Zuazu J, de la Rubia J, Bargay J, Caballero D, Diez-Martin JL, et al. Allogeneic transplantation of CD34\u2009+\u2009-selected cells from peripheral blood in patients with myeloid malignancies in early phase: a case control comparison with unmodified peripheral blood transplantation. Bone Marrow Transplant. 2001;28:349\u201354.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR16","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.1182\/blood-2011-01-329821","volume":"117","author":"G Socie","year":"2011","unstructured":"Socie G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood. 2011;117:6375\u201382.","journal-title":"Blood"},{"key":"281_CR17","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1182\/blood-2002-03-0701","volume":"100","author":"JA Perez-Simon","year":"2002","unstructured":"Perez-Simon JA, Kottaridis PD, Martino R, Craddock C, Caballero D, Chopra R, Garcia-Conde J, Milligan DW, Schey S, Urbano-Ispizua A, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood. 2002;100:3121\u20137.","journal-title":"Blood"},{"key":"281_CR18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kroger","year":"2016","unstructured":"Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"281_CR19","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev.immunol.25.022106.141623","volume":"30","author":"SZ Josefowicz","year":"2012","unstructured":"Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531\u201364.","journal-title":"Annu Rev Immunol"},{"key":"281_CR20","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","volume":"14","author":"A Liston","year":"2014","unstructured":"Liston A, Gray DH. Homeostatic control of regulatory T cell diversity. Nat Rev Immunol. 2014;14:154\u201365.","journal-title":"Nat Rev Immunol"},{"key":"281_CR21","doi-asserted-by":"publisher","unstructured":"Humblet-Baron S, Franckaert D, Dooley J, Bornschein S, Cauwe B, Schonefeldt S, Bossuyt X, Matthys P, Baron F, Wouters C, Liston A. IL-2 consumption by highly activated CD8 T cells induces regulatory T-cell dysfunction in patients with hemophagocytic lymphohistiocytosis. J Allergy Clin Immunol. 2016. doi: 10.1016\/j.jaci.2015.12.1314 . [Epub ahead of print].","DOI":"10.1016\/j.jaci.2015.12.1314"},{"key":"281_CR22","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2011-06-362137","volume":"118","author":"Y Kawano","year":"2011","unstructured":"Kawano Y, Kim HT, Matsuoka K, Bascug G, McDonough S, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, et al. Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011;118:5021\u201330.","journal-title":"Blood"},{"key":"281_CR23","doi-asserted-by":"crossref","first-page":"179ra143","DOI":"10.1126\/scitranslmed.3005265","volume":"5","author":"K Matsuoka","year":"2013","unstructured":"Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, Murase K, Cutler C, Ho VT, Alyea EP, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5:179ra143.","journal-title":"Sci Transl Med"},{"key":"281_CR24","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1182\/blood-2005-09-3623","volume":"107","author":"C Zhang","year":"2006","unstructured":"Zhang C, Todorov I, Zhang Z, Liu Y, Kandeel F, Forman S, Strober S, Zeng D. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107:2993\u20133001.","journal-title":"Blood"},{"key":"281_CR25","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/bmt.2013.215","volume":"49","author":"F Malard","year":"2014","unstructured":"Malard F, Bossard C, Brissot E, Chevallier P, Guillaume T, Delaunay J, Mosnier JF, Moreau P, Gregoire M, Gaugler B, Mohty M. Increased Th17\/Treg ratio in chronic liver GVHD. Bone Marrow Transplant. 2014;49:539\u201344.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR26","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2008-02-140277","volume":"112","author":"D Zhao","year":"2008","unstructured":"Zhao D, Zhang C, Yi T, Lin CL, Todorov I, Kandeel F, Forman S, Zeng D. In vivo-activated CD103\u2009+\u2009CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood. 2008;112:2129\u201338.","journal-title":"Blood"},{"key":"281_CR27","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","volume":"4","author":"JD Fontenot","year":"2003","unstructured":"Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4\u2009+\u2009CD25+ regulatory T cells. Nat Immunol. 2003;4:330\u20136.","journal-title":"Nat Immunol"},{"key":"281_CR28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.immuni.2013.03.002","volume":"38","author":"N Ohkura","year":"2013","unstructured":"Ohkura N, Kitagawa Y, Sakaguchi S. Development and maintenance of regulatory T cells. Immunity. 2013;38:414\u201323.","journal-title":"Immunity"},{"key":"281_CR29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.4049\/jimmunol.182.1.259","volume":"182","author":"G Lal","year":"2009","unstructured":"Lal G, Zhang N, van der Touw W, Ding Y, Ju W, Bottinger EP, Reid SP, Levy DE, Bromberg JS. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J Immunol. 2009;182:259\u201373.","journal-title":"J Immunol"},{"key":"281_CR30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2009-03-210393","volume":"115","author":"LI Sanchez-Abarca","year":"2010","unstructured":"Sanchez-Abarca LI, Gutierrez-Cosio S, Santamaria C, Caballero-Velazquez T, Blanco B, Herrero-Sanchez C, Garcia JL, Carrancio S, Hernandez-Campo P, Gonzalez FJ, et al. Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting. Blood. 2010;115:107\u201321.","journal-title":"Blood"},{"key":"281_CR31","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"116","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL, Holt M, Shannon WD, Deych E, Piwnica-Worms DR, DiPersio JF. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood. 2010;116:129\u201339.","journal-title":"Blood"},{"key":"281_CR32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0008-8749(83)90001-1","volume":"77","author":"BD Jaffee","year":"1983","unstructured":"Jaffee BD, Claman HN. Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol. 1983;77:1\u201312.","journal-title":"Cell Immunol"},{"key":"281_CR33","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.bbmt.2007.12.002","volume":"14","author":"YW Chu","year":"2008","unstructured":"Chu YW, Gress RE. Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant. 2008;14:365\u201378.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1242\/dmm.006668","volume":"4","author":"MA Schroeder","year":"2011","unstructured":"Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4:318\u201333.","journal-title":"Dis Model Mech"},{"key":"281_CR35","doi-asserted-by":"crossref","first-page":"e113764","DOI":"10.1371\/journal.pone.0113764","volume":"9","author":"M Binsfeld","year":"2014","unstructured":"Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, et al. Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation. PLoS One. 2014;9:e113764.","journal-title":"PLoS One"},{"key":"281_CR36","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467\u201370.","journal-title":"J Clin Pathol"},{"key":"281_CR37","doi-asserted-by":"crossref","first-page":"43255","DOI":"10.18632\/oncotarget.6486","volume":"6","author":"G Ehx","year":"2015","unstructured":"Ehx G, Hannon M, Beguin Y, Humblet-Baron S, Baron F. Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget. 2015;6:43255\u201366.","journal-title":"Oncotarget"},{"key":"281_CR38","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1158\/1078-0432.CCR-14-3374","volume":"21","author":"M Hannon","year":"2015","unstructured":"Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, et al. Immune recovery after allogeneic hematopoietic stem cell transplantation following Flu-TBI versus TLI-ATG conditioning. Clin Cancer Res. 2015;21:3131\u20139.","journal-title":"Clin Cancer Res"},{"key":"281_CR39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/978-1-59745-522-0_20","volume":"507","author":"CC Oakes","year":"2009","unstructured":"Oakes CC, La Salle S, Trasler JM, Robaire B. Restriction digestion and real-time PCR (qAMP). Methods Mol Biol. 2009;507:271\u201380.","journal-title":"Methods Mol Biol"},{"key":"281_CR40","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1093\/nar\/18.15.4523","volume":"18","author":"TJ Novak","year":"1990","unstructured":"Novak TJ, White PM, Rothenberg EV. Regulatory anatomy of the murine interleukin-2 gene. Nucleic Acids Res. 1990;18:4523\u201333.","journal-title":"Nucleic Acids Res"},{"key":"281_CR41","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/blood-2011-12-396119","volume":"119","author":"RJ Robb","year":"2012","unstructured":"Robb RJ, Lineburg KE, Kuns RD, Wilson YA, Raffelt NC, Olver SD, Varelias A, Alexander KA, Teal BE, Sparwasser T, et al. Identification and expansion of highly suppressive CD8(+)FoxP3(+) regulatory T cells after experimental allogeneic bone marrow transplantation. Blood. 2012;119:5898\u2013908.","journal-title":"Blood"},{"key":"281_CR42","doi-asserted-by":"crossref","first-page":"464","DOI":"10.4049\/jimmunol.1200886","volume":"189","author":"AJ Beres","year":"2012","unstructured":"Beres AJ, Haribhai D, Chadwick AC, Gonyo PJ, Williams CB, Drobyski WR. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity. J Immunol. 2012;189:464\u201374.","journal-title":"J Immunol"},{"key":"281_CR43","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2007-06-094482","volume":"111","author":"R Zeiser","year":"2008","unstructured":"Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4\u2009+\u2009CD25\u2009+\u2009Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111:453\u201362.","journal-title":"Blood"},{"key":"281_CR44","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4049\/jimmunol.133.1.7","volume":"133","author":"ZK Ballas","year":"1984","unstructured":"Ballas ZK. The use of 5-azacytidine to establish constitutive interleukin 2-producing clones of the EL4 thymoma. J Immunol. 1984;133:7\u20139.","journal-title":"J Immunol"},{"key":"281_CR45","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1038\/sj.emboj.7601012","volume":"25","author":"A Murayama","year":"2006","unstructured":"Murayama A, Sakura K, Nakama M, Yasuzawa-Tanaka K, Fujita E, Tateishi Y, Wang Y, Ushijima T, Baba T, Shibuya K, et al. A specific CpG site demethylation in the human interleukin 2 gene promoter is an epigenetic memory. EMBO J. 2006;25:1081\u201392.","journal-title":"EMBO J"},{"key":"281_CR46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ni887","volume":"4","author":"D Bruniquel","year":"2003","unstructured":"Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol. 2003;4:235\u201340.","journal-title":"Nat Immunol"},{"key":"281_CR47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3324\/haematol.2010.029702","volume":"96","author":"E Castermans","year":"2011","unstructured":"Castermans E, Hannon M, Dutrieux J, Humblet-Baron S, Seidel L, Cheynier R, Willems E, Gothot A, Vanbellinghen JF, Geenen V, et al. Thymic recovery after allogeneic hematopoietic cell transplantation with non-myeloablative conditioning is limited to patients younger than 60\u00a0years of age. Haematologica. 2011;96:298\u2013306.","journal-title":"Haematologica"},{"key":"281_CR48","doi-asserted-by":"crossref","first-page":"488","DOI":"10.4049\/jimmunol.1300657","volume":"191","author":"T Wu","year":"2013","unstructured":"Wu T, Young JS, Johnston H, Ni X, Deng R, Racine J, Wang M, Wang A, Todorov I, Wang J, Zeng D. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells. J Immunol. 2013;191:488\u201399.","journal-title":"J Immunol"},{"key":"281_CR49","doi-asserted-by":"crossref","unstructured":"Ehx G, Fransolet G, De Leval L, D\u2019Hondt S, Lucas S, Hannon M, Delens L, Dubois S, Drion P, Beguin Y, et al. Azacytidine enhances regulatory T-cells in vivo and prevents experimental xenogeneic graft-versus-host disease. Biol Blood Marrow Transplant. 2016;22:s393\u20133.","DOI":"10.1016\/j.bbmt.2015.11.917"},{"key":"281_CR50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-016-0263-4","volume":"9","author":"L Pleyer","year":"2016","unstructured":"Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, Thaler J, Halter B, Machherndl-Spandl S, Zebisch A, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016;9:39.","journal-title":"J Hematol Oncol"},{"key":"281_CR51","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1756-8722-6-29","volume":"6","author":"LH Helm van der","year":"2013","unstructured":"van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, Vellenga E, Huls G. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.","journal-title":"J Hematol Oncol"},{"key":"281_CR52","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/bmt.2015.10","volume":"50","author":"J Steinmann","year":"2015","unstructured":"Steinmann J, Bertz H, Wasch R, Marks R, Zeiser R, Bogatyreva L, Finke J, Lubbert M. 5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. Bone Marrow Transplant. 2015;50:690\u20135.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR53","doi-asserted-by":"crossref","unstructured":"Craddock C, Jilani NY, Siddique S, Yap C, Khan JN, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, et al. Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial. Biol Blood Marrow Transplant. 2015.","DOI":"10.1016\/j.bbmt.2015.09.004"},{"key":"281_CR54","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC, Dennis M, Jilani NY, Loke J, Siddique S, Ryan G, Nunnick J, Khanum R, Raghavan M, Cook M, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood. 2012;119:3361\u20139.","journal-title":"Blood"},{"key":"281_CR55","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/bmt.2013.204","volume":"49","author":"F Baron","year":"2014","unstructured":"Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socie G, et al. Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014;49:389\u201396.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR56","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/23287","volume":"400","author":"W Yu","year":"1999","unstructured":"Yu W, Nagaoka H, Jankovic M, Misulovin Z, Suh H, Rolink A, Melchers F, Meffre E, Nussenzweig MC. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization. Nature. 1999;400:682\u20137.","journal-title":"Nature"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-016-0281-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T02:06:37Z","timestamp":1718676397000},"score":1,"resource":{"primary":{"URL":"http:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-016-0281-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1186\/s13045-016-0281-2","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,4]]},"article-number":"53"}}